Startup promises face time with IBM's Watson

Share this article:

Digital health startup Welltok said yesterday that it had received $22.1 million in Series C funding from IBM and Qualcomm Ventures' life fund portfolio.

Welltok is currently developing a health optimization platform, CafeWell. The company says the platform helps population health managers organize "the expanding ecosystem of health and wellness solutions," like apps and tracking devices and delivers a consumer platform that offers incentives for certain activities. It cites a premium reduction for lowering your body mass index (BMI) as an example.

Welltok stated that it plans to use the additional funding to harness IBM's Watson "to address consumer questions about their health conditions and activities through personalized dialogue and guide them via Intelligent Health Itineraries," as well as expand CafeWell's solutions for health plans, ACOs, and add new partners "that are creating communities, innovative condition management, and wellness programs, tracking devices and applications."

SVP of the IBM Watson Group Mike Rhodin stated, "This investment and partnership represent IBM's dedication to fueling innovation that improves lives and our mission to advance the field of health care into the new era of cognitive computing."

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.